Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1–August 20, 2021): a retrospective observational monocentric study
Abstract Background Monoclonal antibodies (mAb) prevent COVID-19 progression when administered early. We compared mAb treatment outcomes among vaccinated and unvaccinated patients during Delta wave and assessed the feasibility of implementing stricter eligibility criteria in the event of mAb scarcit...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-07-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-022-07626-6 |
| _version_ | 1811222919545618432 |
|---|---|
| author | Yi Guo Kelsie Cowman Mei Chang Hongkai Bao Austin Golia Terrence Mcsweeney Linda Bard Roxanne Simpson Erin Andrews Liise-anne Pirofski Priya Nori |
| author_facet | Yi Guo Kelsie Cowman Mei Chang Hongkai Bao Austin Golia Terrence Mcsweeney Linda Bard Roxanne Simpson Erin Andrews Liise-anne Pirofski Priya Nori |
| author_sort | Yi Guo |
| collection | DOAJ |
| description | Abstract Background Monoclonal antibodies (mAb) prevent COVID-19 progression when administered early. We compared mAb treatment outcomes among vaccinated and unvaccinated patients during Delta wave and assessed the feasibility of implementing stricter eligibility criteria in the event of mAb scarcity. Methods We conducted a retrospective observational study of casirivimab/imdevimab recipients with mild-to-moderate COVID-19 infection in an emergency department or outpatient infusion center (July 1–August 20, 2021). Primary outcome was all-cause hospital admission within 30 days post-treatment between vaccinated vs. unvaccinated patients during Delta surge in the Bronx, NY. Results A total of 250 patients received casirivimab/imdevimab (162 unvaccinated vs. 88 vaccinated). The median age was 39 years for unvaccinated patients, and 52 years for vaccinated patients (p < 0.0001). The median number of EUA criteria met was 1 for unvaccinated and 2 for vaccinated patients (p < 0.0001). Overall, 6% (15/250) of patients were admitted within 30 days post-treatment. Eleven unvaccinated patients (7%) were admitted within 30-days compared to 4 (5%) vaccinated patients (p = 0.48). Conclusions All-cause 30-day admission was not statistically different between vaccinated and unvaccinated patients. When federal allocation of therapies is limited, programs must prioritize patients at highest risk of hospitalization and death regardless of vaccination status. |
| first_indexed | 2024-04-12T08:24:22Z |
| format | Article |
| id | doaj.art-6064323048a74efe8845e07ad13be6e4 |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-04-12T08:24:22Z |
| publishDate | 2022-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-6064323048a74efe8845e07ad13be6e42022-12-22T03:40:27ZengBMCBMC Infectious Diseases1471-23342022-07-012211810.1186/s12879-022-07626-6Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1–August 20, 2021): a retrospective observational monocentric studyYi Guo0Kelsie Cowman1Mei Chang2Hongkai Bao3Austin Golia4Terrence Mcsweeney5Linda Bard6Roxanne Simpson7Erin Andrews8Liise-anne Pirofski9Priya Nori10Department of Pharmacy, Montefiore Medical Center MosesDivision of Infectious Diseases, Department of Medicine, Montefiore Medical Center, Albert Einstein College of MedicineDepartment of Pharmacy, Montefiore Medical Center WeilerDepartment of Pharmacy, Montefiore Medical Center WakefieldDepartment of Pharmacy, Montefiore Medical Center MosesDepartment of Pharmacy, Montefiore Medical Center MosesFaculty Practice Group, Montefiore Medical CenterDepartment of Nursing, Montefiore Medical CenterNetwork Performance Group, Montefiore Health SystemDivision of Infectious Diseases, Department of Microbiology and Immunology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of MedicineDivision of Infectious Diseases, Department of Medicine, Montefiore Medical Center, Albert Einstein College of MedicineAbstract Background Monoclonal antibodies (mAb) prevent COVID-19 progression when administered early. We compared mAb treatment outcomes among vaccinated and unvaccinated patients during Delta wave and assessed the feasibility of implementing stricter eligibility criteria in the event of mAb scarcity. Methods We conducted a retrospective observational study of casirivimab/imdevimab recipients with mild-to-moderate COVID-19 infection in an emergency department or outpatient infusion center (July 1–August 20, 2021). Primary outcome was all-cause hospital admission within 30 days post-treatment between vaccinated vs. unvaccinated patients during Delta surge in the Bronx, NY. Results A total of 250 patients received casirivimab/imdevimab (162 unvaccinated vs. 88 vaccinated). The median age was 39 years for unvaccinated patients, and 52 years for vaccinated patients (p < 0.0001). The median number of EUA criteria met was 1 for unvaccinated and 2 for vaccinated patients (p < 0.0001). Overall, 6% (15/250) of patients were admitted within 30 days post-treatment. Eleven unvaccinated patients (7%) were admitted within 30-days compared to 4 (5%) vaccinated patients (p = 0.48). Conclusions All-cause 30-day admission was not statistically different between vaccinated and unvaccinated patients. When federal allocation of therapies is limited, programs must prioritize patients at highest risk of hospitalization and death regardless of vaccination status.https://doi.org/10.1186/s12879-022-07626-6Coronavirus disease 19COVID-19Delta variantSARS-CoV-2 variant B.1.617.2Monoclonal antibodyCasirivimab/imdevimab |
| spellingShingle | Yi Guo Kelsie Cowman Mei Chang Hongkai Bao Austin Golia Terrence Mcsweeney Linda Bard Roxanne Simpson Erin Andrews Liise-anne Pirofski Priya Nori Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1–August 20, 2021): a retrospective observational monocentric study BMC Infectious Diseases Coronavirus disease 19 COVID-19 Delta variant SARS-CoV-2 variant B.1.617.2 Monoclonal antibody Casirivimab/imdevimab |
| title | Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1–August 20, 2021): a retrospective observational monocentric study |
| title_full | Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1–August 20, 2021): a retrospective observational monocentric study |
| title_fullStr | Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1–August 20, 2021): a retrospective observational monocentric study |
| title_full_unstemmed | Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1–August 20, 2021): a retrospective observational monocentric study |
| title_short | Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1–August 20, 2021): a retrospective observational monocentric study |
| title_sort | assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 covid 19 treated with monoclonal antibodies during the delta wave july 1 august 20 2021 a retrospective observational monocentric study |
| topic | Coronavirus disease 19 COVID-19 Delta variant SARS-CoV-2 variant B.1.617.2 Monoclonal antibody Casirivimab/imdevimab |
| url | https://doi.org/10.1186/s12879-022-07626-6 |
| work_keys_str_mv | AT yiguo assessmentofunvaccinatedandvaccinatedpatientswithcoronavirusdisease2019covid19treatedwithmonoclonalantibodiesduringthedeltawavejuly1august202021aretrospectiveobservationalmonocentricstudy AT kelsiecowman assessmentofunvaccinatedandvaccinatedpatientswithcoronavirusdisease2019covid19treatedwithmonoclonalantibodiesduringthedeltawavejuly1august202021aretrospectiveobservationalmonocentricstudy AT meichang assessmentofunvaccinatedandvaccinatedpatientswithcoronavirusdisease2019covid19treatedwithmonoclonalantibodiesduringthedeltawavejuly1august202021aretrospectiveobservationalmonocentricstudy AT hongkaibao assessmentofunvaccinatedandvaccinatedpatientswithcoronavirusdisease2019covid19treatedwithmonoclonalantibodiesduringthedeltawavejuly1august202021aretrospectiveobservationalmonocentricstudy AT austingolia assessmentofunvaccinatedandvaccinatedpatientswithcoronavirusdisease2019covid19treatedwithmonoclonalantibodiesduringthedeltawavejuly1august202021aretrospectiveobservationalmonocentricstudy AT terrencemcsweeney assessmentofunvaccinatedandvaccinatedpatientswithcoronavirusdisease2019covid19treatedwithmonoclonalantibodiesduringthedeltawavejuly1august202021aretrospectiveobservationalmonocentricstudy AT lindabard assessmentofunvaccinatedandvaccinatedpatientswithcoronavirusdisease2019covid19treatedwithmonoclonalantibodiesduringthedeltawavejuly1august202021aretrospectiveobservationalmonocentricstudy AT roxannesimpson assessmentofunvaccinatedandvaccinatedpatientswithcoronavirusdisease2019covid19treatedwithmonoclonalantibodiesduringthedeltawavejuly1august202021aretrospectiveobservationalmonocentricstudy AT erinandrews assessmentofunvaccinatedandvaccinatedpatientswithcoronavirusdisease2019covid19treatedwithmonoclonalantibodiesduringthedeltawavejuly1august202021aretrospectiveobservationalmonocentricstudy AT liiseannepirofski assessmentofunvaccinatedandvaccinatedpatientswithcoronavirusdisease2019covid19treatedwithmonoclonalantibodiesduringthedeltawavejuly1august202021aretrospectiveobservationalmonocentricstudy AT priyanori assessmentofunvaccinatedandvaccinatedpatientswithcoronavirusdisease2019covid19treatedwithmonoclonalantibodiesduringthedeltawavejuly1august202021aretrospectiveobservationalmonocentricstudy |